false Q2 --12-31 0001069394 0001069394 2025-01-01 2025-06-30 0001069394 2025-08-14 0001069394 2025-06-30 0001069394 2024-12-31 0001069394 2025-04-01 2025-06-30 0001069394 2024-04-01 2024-06-30 0001069394 us-gaap:ProductMember 2025-04-01 2025-06-30 0001069394 us-gaap:ProductMember 2024-04-01 2024-06-30 0001069394 FSI:ResearchAndDevelopmentServicesMember 2025-04-01 2025-06-30 0001069394 FSI:ResearchAndDevelopmentServicesMember 2024-04-01 2024-06-30 0001069394 2024-01-01 2024-06-30 0001069394 us-gaap:ProductMember 2025-01-01 2025-06-30 0001069394 us-gaap:ProductMember 2024-01-01 2024-06-30 0001069394 FSI:ResearchAndDevelopmentServicesMember 2025-01-01 2025-06-30 0001069394 FSI:ResearchAndDevelopmentServicesMember 2024-01-01 2024-06-30 0001069394 2023-12-31 0001069394 2024-06-30 0001069394 us-gaap:CommonStockMember 2024-12-31 0001069394 FSI:CapitalInExcessOfParValueMember 2024-12-31 0001069394 us-gaap:RetainedEarningsMember 2024-12-31 0001069394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001069394 us-gaap:ParentMember 2024-12-31 0001069394 us-gaap:NoncontrollingInterestMember 2024-12-31 0001069394 us-gaap:CommonStockMember 2025-03-31 0001069394 FSI:CapitalInExcessOfParValueMember 2025-03-31 0001069394 us-gaap:RetainedEarningsMember 2025-03-31 0001069394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001069394 us-gaap:ParentMember 2025-03-31 0001069394 us-gaap:NoncontrollingInterestMember 2025-03-31 0001069394 2025-03-31 0001069394 us-gaap:CommonStockMember 2023-12-31 0001069394 FSI:CapitalInExcessOfParValueMember 2023-12-31 0001069394 us-gaap:RetainedEarningsMember 2023-12-31 0001069394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001069394 us-gaap:ParentMember 2023-12-31 0001069394 us-gaap:NoncontrollingInterestMember 2023-12-31 0001069394 us-gaap:CommonStockMember 2024-03-31 0001069394 FSI:CapitalInExcessOfParValueMember 2024-03-31 0001069394 us-gaap:RetainedEarningsMember 2024-03-31 0001069394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001069394 us-gaap:ParentMember 2024-03-31 0001069394 us-gaap:NoncontrollingInterestMember 2024-03-31 0001069394 2024-03-31 0001069394 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001069394 FSI:CapitalInExcessOfParValueMember 2025-01-01 2025-03-31 0001069394 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001069394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001069394 us-gaap:ParentMember 2025-01-01 2025-03-31 0001069394 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-31 0001069394 2025-01-01 2025-03-31 0001069394 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001069394 FSI:CapitalInExcessOfParValueMember 2025-04-01 2025-06-30 0001069394 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001069394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0001069394 us-gaap:ParentMember 2025-04-01 2025-06-30 0001069394 us-gaap:NoncontrollingInterestMember 2025-04-01 2025-06-30 0001069394 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001069394 FSI:CapitalInExcessOfParValueMember 2024-01-01 2024-03-31 0001069394 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001069394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001069394 us-gaap:ParentMember 2024-01-01 2024-03-31 0001069394 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0001069394 2024-01-01 2024-03-31 0001069394 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001069394 FSI:CapitalInExcessOfParValueMember 2024-04-01 2024-06-30 0001069394 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001069394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001069394 us-gaap:ParentMember 2024-04-01 2024-06-30 0001069394 us-gaap:NoncontrollingInterestMember 2024-04-01 2024-06-30 0001069394 us-gaap:CommonStockMember 2025-06-30 0001069394 FSI:CapitalInExcessOfParValueMember 2025-06-30 0001069394 us-gaap:RetainedEarningsMember 2025-06-30 0001069394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001069394 us-gaap:ParentMember 2025-06-30 0001069394 us-gaap:NoncontrollingInterestMember 2025-06-30 0001069394 us-gaap:CommonStockMember 2024-06-30 0001069394 FSI:CapitalInExcessOfParValueMember 2024-06-30 0001069394 us-gaap:RetainedEarningsMember 2024-06-30 0001069394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001069394 us-gaap:ParentMember 2024-06-30 0001069394 us-gaap:NoncontrollingInterestMember 2024-06-30 0001069394 FSI:MendotaLLCMember 2025-01-01 2025-06-30 0001069394 FSI:ENPInvestmentsLLCAndENPMendotaMember 2025-01-01 2025-06-30 0001069394 FSI:ENPPeruMember FSI:UnrelatedPartyMember 2022-01-01 2022-12-31 0001069394 FSI:ENPPeruMember 2022-01-01 2022-12-31 0001069394 FSI:ENPInvestmentsAndENPMendotaMember 2022-01-01 2022-12-31 0001069394 FSI:ENPPeruMember 2023-01-01 2023-12-31 0001069394 FSI:MendotaLLCMember 2023-01-01 2023-12-31 0001069394 FSI:MendotaLLCMember FSI:UnrelatedPartyMember 2023-12-31 0001069394 FSI:FirstTermMember 2025-06-30 0001069394 FSI:SecondTermMember 2025-06-30 0001069394 FSI:ThirdTermMember 2025-06-30 0001069394 us-gaap:ShippingAndHandlingMember 2025-04-01 2025-06-30 0001069394 us-gaap:ShippingAndHandlingMember 2024-04-01 2024-06-30 0001069394 us-gaap:ShippingAndHandlingMember 2025-01-01 2025-06-30 0001069394 us-gaap:ShippingAndHandlingMember 2024-01-01 2024-06-30 0001069394 FSI:ThreePrimaryCustomersMember us-gaap:RevenueFromContractWithCustomerMember 2025-04-01 2025-06-30 0001069394 FSI:ThreePrimaryCustomersMember us-gaap:RevenueFromContractWithCustomerMember 2024-04-01 2024-06-30 0001069394 FSI:ThreePrimaryCustomersMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-06-30 0001069394 FSI:ThreePrimaryCustomersMember us-gaap:RevenueFromContractWithCustomerMember 2024-01-01 2024-06-30 0001069394 FSI:ThreePrimaryCustomersMember us-gaap:ResearchAndDevelopmentExpenseMember 2025-04-01 2025-06-30 0001069394 FSI:ThreePrimaryCustomersMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001069394 FSI:ThreePrimaryCustomersMember us-gaap:ResearchAndDevelopmentExpenseMember 2025-01-01 2025-06-30 0001069394 FSI:ThreePrimaryCustomersMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001069394 FSI:ThreePrimaryCustomersMember us-gaap:AccountsReceivableMember 2025-01-01 2025-06-30 0001069394 FSI:ThreePrimaryCustomersMember us-gaap:AccountsReceivableMember 2024-01-01 2024-12-31 0001069394 FSI:ThreePrimaryCustomersMember FSI:AccountsReceivableResearchAndDevelopmentMember 2025-01-01 2025-06-30 0001069394 FSI:ThreePrimaryCustomersMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-12-31 0001069394 us-gaap:BuildingAndBuildingImprovementsMember 2025-06-30 0001069394 us-gaap:AutomobilesMember 2025-06-30 0001069394 us-gaap:OfficeEquipmentMember 2025-06-30 0001069394 us-gaap:MachineryAndEquipmentMember 2025-06-30 0001069394 us-gaap:LandMember 2025-06-30 0001069394 FSI:TechnologyMember 2025-06-30 0001069394 us-gaap:BuildingAndBuildingImprovementsMember 2024-12-31 0001069394 us-gaap:AutomobilesMember 2024-12-31 0001069394 us-gaap:OfficeEquipmentMember 2024-12-31 0001069394 us-gaap:MachineryAndEquipmentMember 2024-12-31 0001069394 us-gaap:LandMember 2024-12-31 0001069394 FSI:TechnologyMember 2024-12-31 0001069394 FSI:FloridaBasedLLCMember 2025-01-01 2025-06-30 0001069394 FSI:LygosIncMember 2025-06-30 0001069394 FSI:LygosIncMember 2024-12-31 0001069394 FSI:TrioOpportunityCorpMember 2025-06-30 0001069394 FSI:TrioOpportunityCorpMember 2024-12-31 0001069394 FSI:FloridaBasedLLCMember 2025-06-30 0001069394 FSI:FloridaBasedLLCMember 2024-12-31 0001069394 us-gaap:CommonClassBMember FSI:TrioOpportunityCorpMember 2025-06-30 0001069394 us-gaap:CommonClassBMember FSI:TrioOpportunityCorpMember 2024-12-31 0001069394 FSI:FloridaBasedLLCMember 2019-01-31 0001069394 FSI:FloridaBasedLLCMember 2024-08-31 0001069394 FSI:FloridaBasedLLCMember 2024-08-01 2024-08-31 0001069394 FSI:FloridaBasedLLCMember 2025-01-01 0001069394 FSI:FloridaBasedLLCMember 2025-04-01 2025-06-30 0001069394 FSI:FloridaBasedLLCMember 2024-04-01 2024-06-30 0001069394 FSI:FloridaBasedLLCMember 2024-01-01 2024-06-30 0001069394 FSI:FloridaBasedLLCMember 2023-12-31 0001069394 FSI:FloridaBasedLLCMember 2024-01-01 2024-12-31 0001069394 FSI:FloridaBasedLLCMember 2023-12-31 0001069394 FSI:FloridaBasedLLCMember 2024-12-31 0001069394 FSI:FloridaBasedLLCMember 2025-06-30 0001069394 FSI:StockBankMember FSI:ENPInvestmentsLLCMember FSI:NewAgreementMember 2025-06-30 0001069394 FSI:StockBankMember FSI:ENPInvestmentsLLCMember FSI:NewAgreementMember srt:MinimumMember 2025-06-01 2025-06-30 0001069394 FSI:StockBankMember FSI:ENPInvestmentsLLCMember FSI:NewAgreementMember srt:MaximumMember 2025-06-01 2025-06-30 0001069394 FSI:StockBankMember FSI:ENPInvestmentsLLCMember FSI:NewAgreementMember 2025-06-01 2025-06-30 0001069394 FSI:StockBankMember FSI:ENPInvestmentsLLCMember FSI:NewAgreementMember 2024-12-31 0001069394 FSI:StockBankMember FSI:NewAgreementMember FSI:NanoChemSolutionIncMember 2025-06-30 0001069394 FSI:NewAgreementMember FSI:NanoChemSolutionIncMember FSI:StockYardAndBankMember 2025-06-30 0001069394 FSI:NoncontrollingInterestsMember FSI:StockBankMember 2025-06-30 0001069394 FSI:StockBankMember FSI:NewAgreementMember 2024-08-31 0001069394 FSI:StockBankMember FSI:NewAgreementMember 2024-08-01 2024-08-31 0001069394 FSI:StockBankMember FSI:NewAgreementMember 2025-06-30 0001069394 FSI:StockBankMember FSI:NewAgreementMember 2024-12-31 0001069394 FSI:StockYardsBankAndTrustMember FSI:TermLoanMember FSI:ENPMendotaMember 2025-06-30 0001069394 FSI:StockYardsBankAndTrustMember FSI:TermLoanMember FSI:ENPMendotaMember 2024-12-31 0001069394 FSI:StockYardsBankAndTrustMember FSI:TermLoanMember FSI:NanoChemMember 2025-06-30 0001069394 FSI:StockYardsBankAndTrustMember FSI:TermLoanMember FSI:NanoChemMember 2024-12-31 0001069394 FSI:StockYardsBankAndTrustMember FSI:TermLoanMember FSI:ENPPeruOneMember 2025-06-30 0001069394 FSI:StockYardsBankAndTrustMember FSI:TermLoanMember FSI:ENPPeruOneMember 2024-12-31 0001069394 FSI:StockYardsBankAndTrustMember FSI:ENPPeruTwoMember FSI:TermLoanMember 2025-06-30 0001069394 FSI:StockYardsBankAndTrustMember FSI:ENPPeruTwoMember FSI:TermLoanMember 2024-12-31 0001069394 FSI:StockYardsBankAndTrustMember FSI:NanoChemOneMember FSI:TermLoanMember 2025-06-30 0001069394 FSI:StockYardsBankAndTrustMember FSI:NanoChemOneMember FSI:TermLoanMember 2024-12-31 0001069394 FSI:StockYardsBankAndTrustMember FSI:MendotaLLCMember FSI:TermLoanMember 2025-06-30 0001069394 FSI:StockYardsBankAndTrustMember FSI:MendotaLLCMember FSI:TermLoanMember 2024-12-31 0001069394 FSI:StockYardsBankAndTrustMember FSI:NanoChemTwoMember FSI:TermLoanMember 2025-06-30 0001069394 FSI:StockYardsBankAndTrustMember FSI:NanoChemTwoMember FSI:TermLoanMember 2024-12-31 0001069394 FSI:StockYardsBankAndTrustMember 2025-06-30 0001069394 FSI:StockYardsBankAndTrustMember 2024-12-31 0001069394 FSI:TermLoanMember FSI:ENPMendotaMember 2025-01-01 2025-06-30 0001069394 FSI:TermLoanMember FSI:ENPMendotaMember 2024-01-01 2024-12-31 0001069394 FSI:TermLoanMember FSI:ENPMendotaMember 2025-06-30 0001069394 FSI:TermLoanMember FSI:ENPMendotaMember 2024-12-31 0001069394 FSI:TermLoanMember FSI:NanoChemMember 2025-01-01 2025-06-30 0001069394 FSI:TermLoanMember FSI:NanoChemMember 2024-01-01 2024-12-31 0001069394 FSI:TermLoanMember FSI:NanoChemMember 2025-06-30 0001069394 FSI:TermLoanMember FSI:NanoChemMember 2024-12-31 0001069394 FSI:TermLoanMember FSI:ENPPeruOneMember 2025-01-01 2025-06-30 0001069394 FSI:TermLoanMember FSI:ENPPeruOneMember 2024-01-01 2024-12-31 0001069394 FSI:TermLoanMember FSI:ENPPeruOneMember 2025-06-30 0001069394 FSI:TermLoanMember FSI:ENPPeruOneMember 2024-12-31 0001069394 FSI:TermLoanMember FSI:ENPPeruInvestmentsMember 2025-01-01 2025-06-30 0001069394 FSI:TermLoanMember FSI:ENPPeruInvestmentsMember 2024-01-01 2024-12-31 0001069394 FSI:TermLoanMember FSI:ENPPeruInvestmentsMember 2025-06-30 0001069394 FSI:TermLoanMember FSI:ENPPeruInvestmentsMember 2024-12-31 0001069394 FSI:TermLoanMember FSI:NanoChemOneMember 2025-01-01 2025-06-30 0001069394 FSI:TermLoanMember FSI:NanoChemOneMember 2024-01-01 2024-12-31 0001069394 FSI:TermLoanMember FSI:NanoChemOneMember 2025-06-30 0001069394 FSI:TermLoanMember FSI:NanoChemOneMember 2024-12-31 0001069394 FSI:TermLoanMember FSI:MendotaLLCMember 2025-01-01 2025-06-30 0001069394 FSI:TermLoanMember FSI:MendotaLLCMember 2024-01-01 2024-12-31 0001069394 FSI:TermLoanMember FSI:MendotaLLCMember 2025-06-30 0001069394 FSI:TermLoanMember FSI:MendotaLLCMember 2024-12-31 0001069394 FSI:TermLoanMember FSI:NanoChemTwoMember 2025-01-01 2025-06-30 0001069394 FSI:TermLoanMember FSI:NanoChemTwoMember 2024-01-01 2024-12-31 0001069394 FSI:TermLoanMember FSI:NanoChemTwoMember 2025-06-30 0001069394 FSI:TermLoanMember FSI:NanoChemTwoMember 2024-12-31 0001069394 FSI:ConsultantsMember 2025-01-01 2025-06-30 0001069394 FSI:ConsultantsMember 2024-01-01 2024-06-30 0001069394 FSI:EmployeesMember 2025-01-01 2025-06-30 0001069394 FSI:EmployeesMember 2024-01-01 2024-06-30 0001069394 us-gaap:CanadaRevenueAgencyMember 2025-06-30 0001069394 us-gaap:CanadaRevenueAgencyMember 2024-06-30 0001069394 us-gaap:CanadaRevenueAgencyMember 2025-01-01 2025-06-30 0001069394 us-gaap:CanadaRevenueAgencyMember 2024-01-01 2024-06-30 0001069394 srt:MinimumMember 2023-12-31 0001069394 srt:MaximumMember 2023-12-31 0001069394 2024-01-01 2024-12-31 0001069394 srt:MinimumMember 2024-01-01 2024-12-31 0001069394 srt:MaximumMember 2024-01-01 2024-12-31 0001069394 srt:MinimumMember 2024-12-31 0001069394 srt:MaximumMember 2024-12-31 0001069394 srt:MinimumMember 2025-01-01 2025-06-30 0001069394 srt:MaximumMember 2025-01-01 2025-06-30 0001069394 srt:MinimumMember 2025-06-30 0001069394 srt:MaximumMember 2025-06-30 0001069394 FSI:WagesAndAdministrativeSalariesMember 2025-04-01 2025-06-30 0001069394 FSI:WagesAndAdministrativeSalariesMember 2024-04-01 2024-06-30 0001069394 FSI:WagesAndAdministrativeSalariesMember 2025-01-01 2025-06-30 0001069394 FSI:WagesAndAdministrativeSalariesMember 2024-01-01 2024-06-30 0001069394 FSI:ConsultingMember 2025-04-01 2025-06-30 0001069394 FSI:ConsultingMember 2024-04-01 2024-06-30 0001069394 FSI:ConsultingMember 2025-01-01 2025-06-30 0001069394 FSI:ConsultingMember 2024-01-01 2024-06-30 0001069394 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-06-30 0001069394 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001069394 FSI:O2025Q2DividendsMember 2025-01-01 2025-06-30 0001069394 FSI:O2024Q2DividendsMember 2024-01-01 2024-06-30 0001069394 FSI:ENPInvestmentsLLCMember 2025-01-01 2025-06-30 0001069394 FSI:ENPInvestmentsLLCMember 2025-06-30 0001069394 FSI:ENPInvestmentsLLCMember 2025-04-01 2025-06-30 0001069394 FSI:ENPInvestmentsLLCMember 2024-04-01 2024-06-30 0001069394 FSI:ENPInvestmentsLLCMember 2024-01-01 2024-06-30 0001069394 FSI:ENPInvestmentsLLCMember 2024-12-31 0001069394 FSI:MendotaLLCMember 2025-06-30 0001069394 FSI:ENPInvestmentsLLCMember FSI:OwnershipInterestPurchaseAgreementMember 2023-12-31 0001069394 FSI:ENPInvestmentsLLCMember FSI:OwnershipInterestPurchaseAgreementMember 2024-01-01 2024-12-31 0001069394 FSI:ENPInvestmentsLLCMember FSI:OwnershipInterestPurchaseAgreementMember 2024-12-31 0001069394 FSI:ENPInvestmentsLLCMember FSI:OwnershipInterestPurchaseAgreementMember 2025-01-01 2025-06-30 0001069394 FSI:ENPInvestmentsLLCMember FSI:OwnershipInterestPurchaseAgreementMember 2025-06-30 0001069394 FSI:MendotaLLCMember FSI:OwnershipInterestPurchaseAgreementMember 2023-12-31 0001069394 FSI:MendotaLLCMember FSI:OwnershipInterestPurchaseAgreementMember 2024-01-01 2024-12-31 0001069394 FSI:MendotaLLCMember FSI:OwnershipInterestPurchaseAgreementMember 2024-12-31 0001069394 FSI:MendotaLLCMember FSI:OwnershipInterestPurchaseAgreementMember 2025-01-01 2025-06-30 0001069394 FSI:MendotaLLCMember FSI:OwnershipInterestPurchaseAgreementMember 2025-06-30 0001069394 FSI:EWCPMember FSI:SegmentMember us-gaap:ProductMember 2025-04-01 2025-06-30 0001069394 FSI:BCPAMember FSI:SegmentMember us-gaap:ProductMember 2025-04-01 2025-06-30 0001069394 FSI:SegmentMember FSI:OtherMember us-gaap:ProductMember 2025-04-01 2025-06-30 0001069394 FSI:SegmentMember us-gaap:ProductMember 2025-04-01 2025-06-30 0001069394 FSI:EWCPMember FSI:SegmentMember FSI:ResearchAndDevelopmentServicesMember 2025-04-01 2025-06-30 0001069394 FSI:BCPAMember FSI:SegmentMember FSI:ResearchAndDevelopmentServicesMember 2025-04-01 2025-06-30 0001069394 FSI:SegmentMember FSI:OtherMember FSI:ResearchAndDevelopmentServicesMember 2025-04-01 2025-06-30 0001069394 FSI:SegmentMember FSI:ResearchAndDevelopmentServicesMember 2025-04-01 2025-06-30 0001069394 FSI:EWCPMember FSI:SegmentMember 2025-04-01 2025-06-30 0001069394 FSI:BCPAMember FSI:SegmentMember 2025-04-01 2025-06-30 0001069394 FSI:SegmentMember FSI:OtherMember 2025-04-01 2025-06-30 0001069394 FSI:SegmentMember 2025-04-01 2025-06-30 0001069394 FSI:EWCPMember FSI:SegmentMember 2025-06-30 0001069394 FSI:BCPAMember FSI:SegmentMember 2025-06-30 0001069394 FSI:SegmentMember FSI:OtherMember 2025-06-30 0001069394 FSI:SegmentMember 2025-06-30 0001069394 FSI:EWCPMember FSI:SegmentMember us-gaap:ProductMember 2024-04-01 2024-06-30 0001069394 FSI:BCPAMember FSI:SegmentMember us-gaap:ProductMember 2024-04-01 2024-06-30 0001069394 FSI:SegmentMember FSI:OtherMember us-gaap:ProductMember 2024-04-01 2024-06-30 0001069394 FSI:SegmentMember us-gaap:ProductMember 2024-04-01 2024-06-30 0001069394 FSI:EWCPMember FSI:SegmentMember 2024-04-01 2024-06-30 0001069394 FSI:BCPAMember FSI:SegmentMember 2024-04-01 2024-06-30 0001069394 FSI:SegmentMember FSI:OtherMember 2024-04-01 2024-06-30 0001069394 FSI:SegmentMember 2024-04-01 2024-06-30 0001069394 FSI:EWCPMember FSI:SegmentMember 2024-06-30 0001069394 FSI:BCPAMember FSI:SegmentMember 2024-06-30 0001069394 FSI:SegmentMember FSI:OtherMember 2024-06-30 0001069394 FSI:SegmentMember 2024-06-30 0001069394 FSI:EWCPMember FSI:SegmentMember us-gaap:ProductMember 2025-01-01 2025-06-30 0001069394 FSI:BCPAMember FSI:SegmentMember us-gaap:ProductMember 2025-01-01 2025-06-30 0001069394 FSI:SegmentMember FSI:OtherMember us-gaap:ProductMember 2025-01-01 2025-06-30 0001069394 FSI:SegmentMember us-gaap:ProductMember 2025-01-01 2025-06-30 0001069394 FSI:EWCPMember FSI:SegmentMember FSI:ResearchAndDevelopmentServicesMember 2025-01-01 2025-06-30 0001069394 FSI:BCPAMember FSI:SegmentMember FSI:ResearchAndDevelopmentServicesMember 2025-01-01 2025-06-30 0001069394 FSI:SegmentMember FSI:OtherMember FSI:ResearchAndDevelopmentServicesMember 2025-01-01 2025-06-30 0001069394 FSI:SegmentMember FSI:ResearchAndDevelopmentServicesMember 2025-01-01 2025-06-30 0001069394 FSI:EWCPMember FSI:SegmentMember 2025-01-01 2025-06-30 0001069394 FSI:BCPAMember FSI:SegmentMember 2025-01-01 2025-06-30 0001069394 FSI:SegmentMember FSI:OtherMember 2025-01-01 2025-06-30 0001069394 FSI:SegmentMember 2025-01-01 2025-06-30 0001069394 FSI:EWCPMember FSI:SegmentMember us-gaap:ProductMember 2024-01-01 2024-06-30 0001069394 FSI:BCPAMember FSI:SegmentMember us-gaap:ProductMember 2024-01-01 2024-06-30 0001069394 FSI:SegmentMember FSI:OtherMember us-gaap:ProductMember 2024-01-01 2024-06-30 0001069394 FSI:SegmentMember us-gaap:ProductMember 2024-01-01 2024-06-30 0001069394 FSI:EWCPMember FSI:SegmentMember 2024-01-01 2024-06-30 0001069394 FSI:BCPAMember FSI:SegmentMember 2024-01-01 2024-06-30 0001069394 FSI:SegmentMember FSI:OtherMember 2024-01-01 2024-06-30 0001069394 FSI:SegmentMember 2024-01-01 2024-06-30 0001069394 country:CA 2025-04-01 2025-06-30 0001069394 country:CA 2024-04-01 2024-06-30 0001069394 country:CA 2025-01-01 2025-06-30 0001069394 country:CA 2024-01-01 2024-06-30 0001069394 FSI:UnitedStatesandAbroadMember 2025-04-01 2025-06-30 0001069394 FSI:UnitedStatesandAbroadMember 2024-04-01 2024-06-30 0001069394 FSI:UnitedStatesandAbroadMember 2025-01-01 2025-06-30 0001069394 FSI:UnitedStatesandAbroadMember 2024-01-01 2024-06-30 0001069394 country:CA 2025-06-30 0001069394 country:CA 2024-12-31 0001069394 country:US 2025-06-30 0001069394 country:US 2024-12-31 0001069394 us-gaap:SubsequentEventMember 2025-07-01 2025-07-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure FSI:Segments

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2025

OR

☐ | TRANSITION REPORT PURSUANT TO 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________

Commission File Number: 001-31540

FLEXIBLE SOLUTIONS INTERNATIONAL INC.

(Exact Name of registrant as Specified in Its Charter)

Alberta, Canada

Alberta |  | 71-1630889
(State or other jurisdiction of |  | (Employer
incorporation or organization) |  | Identification No.)

6001 54 Ave. |  |
Taber, Alberta, Canada |  | T1G 1X4
(Address of Principal Executive Offices) |  | (Zip Code)

Registrant’s telephone number: (403) 223-2995

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common Stock |  | FSI |  | NYSE American

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ | Accelerated filer ☐
Non-accelerated filer ☒ | Smaller reporting company ☒
Emerging growth company ☐ |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): ☐ Yes ☒ No

Class of Stock |  | No. Shares Outstanding |  | Date
Common |  | 12,656,532 |  | August 14, 2025

FORM 10-Q

Index

PART I. | FINANCIAL INFORMATION | 3
Item 1. | Financial Statements. | 3
| (a) | Unaudited Condensed Interim Consolidated Balance Sheets at June 30, 2025 and December 31, 2024. | 3
| (b) | Unaudited Condensed Interim Consolidated Statements of Operations and Comprehensive Income (Loss) for the Three Months Ended June 30, 2025 and 2024. | 4
| (c) | Unaudited Condensed Interim Consolidated Statements of Operations and Comprehensive Income for the Six Months Ended June 30, 2025 and 2024. | 5
| (d) | Unaudited Condensed Interim Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024. | 6
| (e) | Unaudited Condensed Interim Consolidated Statements of Stockholders’ Equity for the Three and Six Months Ended June 30, 2025 and 2024. | 7
| (f) | Notes to Unaudited Condensed Interim Consolidated Financial Statements for the Period Ended June 30, 2025. | 8
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operation. | 19
Item 4. | Controls and Procedures. | 22
PART II. | OTHER INFORMATION AND EXHIBITS | 22
Item 5. | Other Information. | 22
Item 6. | Exhibits. | 22
SIGNATURES | 23

1

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This document contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are “forward-looking statements” for the purposes of the federal and state securities laws, including, but not limited to: any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing.

Forward-looking statements may include the words “may,” “could,” “will,” “estimate,” “intend,” “continue,” “believe,” “expect” or “anticipate” or other similar words. These forward-looking statements present our estimates and assumptions only as of the date of this report. Except for our ongoing obligation to disclose material information as required by the federal securities laws, we do not intend, and undertake no obligation, to update any forward-looking statement.

Although we believe that the expectations reflected in any of our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and inherent risks and uncertainties. The factors impacting these risks and uncertainties include but are not limited to:

| ● | Increased competitive pressures from existing competitors and new entrants;
| ● | Increases in interest rates or our cost of borrowing or a default under any material debt agreement;
| ● | Deterioration in general or regional economic conditions;
| ● | Adverse state or federal legislation or regulation that increases the costs of compliance, or adverse findings by a regulator with respect to existing operations;
| ● | Loss of customers or sales weakness;
| ● | Inability to achieve future sales levels or other operating results;
| ● | The unavailability of funds for capital expenditures;
| ● | Operational inefficiencies in distribution or other systems; and
| ● | New tariffs relating to raw materials imported from China.

For a detailed description of these and other factors that could cause actual results to differ materially from those expressed in any forward-looking statement, please see “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024.

2

PART I FINANCIAL INFORMATION

Item 1. Financial Statements.

FLEXIBLE SOLUTIONS INTERNATIONAL, INC.

CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS

(U.S. Dollars - Unaudited)

|  | June 30, 2025 |  |  | December 31, 2024 |
Assets |  |  |  |  |  |  |  |
Current |  |  |  |  |  |  |  |
Cash |  | $ | 8,613,182 |  |  | $ | 7,631,055 |
Term deposits (Note 2) |  |  | 1,386,150 |  |  |  | 2,400,916 |
Accounts receivable, net (Note 3) |  |  | 8,599,081 |  |  |  | 11,696,098 |
Inventories (Note 4) |  |  | 11,334,901 |  |  |  | 10,890,195 |
Prepaid expenses and deposits |  |  | 1,158,939 |  |  |  | 1,957,593 |
Total current assets |  |  | 31,092,253 |  |  |  | 34,575,857 |
Property and equipment, net (Note 5) |  |  | 17,597,133 |  |  |  | 17,146,184 |
Intangible assets, net |  |  | 2,040,000 |  |  |  | 2,120,000 |
Long term deposits |  |  | 1,460,346 |  |  |  | 167,882 |
Investments (Note 6) |  |  | 3,510,041 |  |  |  | 3,424,381 |
Goodwill |  |  | 2,534,275 |  |  |  | 2,534,275 |
Total Assets |  | $ | 58,234,048 |  |  | $ | 59,968,579 |
Liabilities |  |  |  |  |  |  |  |
Current |  |  |  |  |  |  |  |
Accounts payable |  | $ | 1,717,913 |  |  | $ | 2,049,425 |
Accrued liabilities |  |  | 208,285 |  |  |  | 403,157 |
Deferred revenue |  |  | 38,200 |  |  |  | 78,655 |
Income taxes payable |  |  | 5,332,799 |  |  |  | 5,137,290 |
Short term lines of credit (Note 7) |  |  | 710,092 |  |  |  | 2,052,159 |
Current portion of long term debt (Note 8) |  |  | 1,144,165 |  |  |  | 2,140,981 |
Total current liabilities |  |  | 9,151,454 |  |  |  | 11,861,667 |
Deferred income tax liability (Note 2) |  |  | 122,019 |  |  |  | 122,019 |
Long term debt (Note 8) |  |  | 6,381,194 |  |  |  | 6,618,867 |
Total Liabilities |  |  | 15,654,667 |  |  |  | 18,602,553 |
Stockholders’ Equity |  |  |  |  |  |  |  |
Capital stock (Note 10) |  |  |  |  |  |  |  |
Authorized: 50,000,000 common shares with a par value of $0.001 each; 1,000,000 preferred shares with a par value of $0.01 each |  |  |  |  |  |  |  |
Issued and outstanding: |  |  |  |  |  |  |  |
12,652,532 (December 31, 2024: 12,515,532) common shares |  |  | 12,653 |  |  |  | 12,516 |
Authorized: 50,000,000 common shares with a par value of $0.001 each; 1,000,000 preferred shares with a par value of $0.01 each Issued and outstanding: 12,652,532 (December 31, 2024: 12,515,532) common shares |  |  | 12,653 |  |  |  | 12,516 |
Capital in excess of par value |  |  | 19,379,508 |  |  |  | 18,789,915 |
Accumulated other comprehensive loss |  |  | (337,632 | ) |  |  | (606,986 | )
Accumulated earnings |  |  | 20,312,952 |  |  |  | 19,836,527 |
Total stockholders’ equity – controlling interest |  |  | 39,367,481 |  |  |  | 38,031,972 |
Non-controlling interests (Note 11) |  |  | 3,211,900 |  |  |  | 3,334,054 |
Total Stockholders’ Equity |  |  | 42,579,381 |  |  |  | 41,366,026 |
Total Liabilities and Stockholders’ Equity |  | $ | 58,234,048 |  |  | $ | 59,968,579 |

— See Notes to Unaudited Condensed Interim Consolidated Financial Statements —

3

FLEXIBLE SOLUTIONS INTERNATIONAL, INC.

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE INCOME

(U.S. Dollars — Unaudited)

|  | 2025 |  |  | 2024 |
|  | Three Months Ended June 30, |
|  | 2025 |  |  | 2024 |
Sales |  |  |  |  |  |
Products |  | $ | 8,867,132 |  |  | $ | 10,528,739 |
Research and development services (Note 2) |  |  | 2,500,000 |  |  |  | - |
Total Sales |  |  | 11,367,132 |  |  |  | 10,528,739 |
Cost of sales |  |  | 5,981,866 |  |  |  | 6,589,644 |
Gross profit |  |  | 5,385,266 |  |  |  | 3,939,095 |
Operating Expenses |  |  |  |  |  |  |  |
Advertising and promotion |  |  | 75,647 |  |  |  | 63,283 |
Commissions |  |  | 19,101 |  |  |  | - |
Consulting |  |  | 41,127 |  |  |  | 142,395 |
Currency exchange |  |  | 34,951 |  |  |  | 47,681 |
Insurance |  |  | 247,632 |  |  |  | 229,198 |
Investor relations and transfer agent fee |  |  | 40,326 |  |  |  | 46,174 |
Lease expense and rent |  |  | 31,108 |  |  |  | 12,195 |
Office and miscellaneous |  |  | 232,836 |  |  |  | 197,707 |
Professional fees |  |  | 150,843 |  |  |  | 122,470 |
Research |  |  | 167,247 |  |  |  | 62,474 |
Shipping |  |  | 11,193 |  |  |  | 7,014 |
Telecommunications |  |  | 23,068 |  |  |  | 15,996 |
Travel |  |  | 30,820 |  |  |  | 61,179 |
Utilities |  |  | 87,463 |  |  |  | 76,256 |
Wages, administrative salaries and benefits |  |  | 894,790 |  |  |  | 884,161 |
Total operating expenses |  |  | 2,088,152 |  |  |  | 1,968,183 |
Operating income |  |  | 3,297,114 |  |  |  | 1,970,912 |
Non-operating income (expense) |  |  |  |  |  |  |  |
Gain on investment |  |  | 21,735 |  |  |  | 115,463 |
Loss on lease termination |  |  |  |  |  |  |  |
Interest expense |  |  | (184,126 | ) |  |  | (157,131 | )
Interest income |  |  | 26,667 |  |  |  | 61,440 |
Total non-operating income (expenses) |  |  | (135,724 | ) |  |  | 19,772 |
Income before income tax |  |  | 3,161,390 |  |  |  | 1,990,684 |
Income taxes |  |  |  |  |  |  |  |
Income tax expense |  |  | (1,016,156 | ) |  |  | (558,251 | )
Net income |  |  | 2,145,234 |  |  |  | 1,432,433 |
Net income attributable to non-controlling interests |  |  | (116,322 | ) |  |  | (142,637 | )
Net income attributable to Flexible Solutions International Inc. |  | $ | 2,028,912 |  |  | $ | 1,289,796 |
Net income per share (basic) |  | $ | 0.16 |  |  | $ | 0.10 |
Net income per share (diluted) |  | $ | 0.15 |  |  | $ | 0.10 |
Weighted average number of common shares (basic) |  |  | 12,647,532 |  |  |  | 12,450,532 |
Weighted average number of common shares (diluted) |  |  | 13,267,333 |  |  |  | 12,480,712 |
Other comprehensive loss: |  |  |  |  |  |  |  |
Net income |  |  | 2,145,234 |  |  |  | 1,432,433 |
Unrealized gain on foreign currency translations |  |  | 80,514 |  |  |  | 35,118 |
Total comprehensive income |  | $ | 2,225,748 |  |  | $ | 1,467,551 |
Comprehensive income – non-controlling interest |  |  | (116,322 | ) |  |  | (142,637 | )
Comprehensive income attributable to Flexible Solutions International Inc. |  | $ | 2,109,426 |  |  | $ | 1,324,914 |

— See Notes to Unaudited Condensed Interim Consolidated Financial Statements —

4

FLEXIBLE SOLUTIONS INTERNATIONAL, INC.

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS AND

COMPREHENSIVE INCOME

(U.S. Dollars — Unaudited)

|  | 2025 |  |  | 2024 |
|  | Six Months Ended June 30, |
|  | 2025 |  |  | 2024 |
Sales |  |  |  |  |  |  |  |
Products |  | $ | 16,340,824 |  |  | $ | 19,753,611 |
Research and development services (Note 2) |  |  | 2,500,000 |  |  |  | - |
Total Sales |  |  | 18,840,824 |  |  |  | 19,753,611 |
Cost of sales |  |  | 11,503,994 |  |  |  | 12,994,149 |
Gross profit |  |  | 7,336,830 |  |  |  | 6,759,462 |
Operating Expenses |  |  |  |  |  |  |  |
Advertising and promotion |  |  | 166,677 |  |  |  | 130,232 |
Commissions |  |  | 19,961 |  |  |  | - |
Consulting |  |  | 142,077 |  |  |  | 242,316 |
Currency exchange |  |  | 34,401 |  |  |  | 46,046 |
Insurance |  |  | 499,829 |  |  |  | 473,458 |
Investor relations and transfer agent fee |  |  | 83,045 |  |  |  | 85,478 |
Lease expense and rent |  |  | 53,268 |  |  |  | 42,345 |
Office and miscellaneous |  |  | 374,955 |  |  |  | 355,330 |
Professional fees |  |  | 312,526 |  |  |  | 183,465 |
Research |  |  | 274,048 |  |  |  | 189,128 |
Shipping |  |  | 21,189 |  |  |  | 14,843 |
Telecommunications |  |  | 34,833 |  |  |  | 29,528 |
Travel |  |  | 79,577 |  |  |  | 127,440 |
Utilities |  |  | 222,460 |  |  |  | 149,932 |
Wages, administrative salaries and benefits |  |  | 1,790,027 |  |  |  | 1,953,178 |
Total operating expenses |  |  | 4,108,873 |  |  |  | 4,022,719 |
Operating income |  |  | 3,227,957 |  |  |  | 2,736,743 |
Non-operating income (expense) |  |  |  |  |  |  |  |
Gain on investment |  |  | 85,660 |  |  |  | 298,438 |
Loss on lease termination |  |  | - |  |  |  | (41,350 | )
Interest expense |  |  | (382,145 | ) |  |  | (332,397 | )
Interest income |  |  | 76,240 |  |  |  | 109,637 |
Total non-operating income (expense) |  |  | (220,245 | ) |  |  | 34,328 |
Income before income tax |  |  | 3,007,712 |  |  |  | 2,771,071 |
Income taxes |  |  |  |  |  |  |  |
Income tax expense |  |  | (1,126,519 | ) |  |  | (822,429 | )
Net income |  |  | 1,881,193 |  |  |  | 1,948,642 |
Net income attributable to non-controlling interests |  |  | (130,015 | ) |  |  | (201,620 | )
Net income attributable to Flexible Solutions International Inc. |  | $ | 1,751,178 |  |  | $ | 1,747,022 |
Net income per share (basic) |  | $ | 0.14 |  |  | $ | 0.14 |
Net income per share (diluted) |  | $ | 0.13 |  |  | $ | 0.14 |
Weighted average number of common shares (basic) |  |  | 12,617,808 |  |  |  | 12,450,118 |
Weighted average number of common shares (diluted) |  |  | 13,382,735 |  |  |  | 12,450,118 |
Other comprehensive loss: |  |  |  |  |  |  |  |
Net income |  | $ | 1,881,193 |  |  | $ | 1,948,642 |
Unrealized gain on foreign currency translations |  |  | 269,354 |  |  |  | 62,341 |
Total comprehensive income |  | $ | 2,150,547 |  |  | $ | 2,010,983 |
Comprehensive income – non-controlling interest |  |  | (130,015 | ) |  |  | (201,620 | )
Comprehensive income attributable to Flexible Solutions International Inc. |  | $ | 2,020,532 |  |  | $ | 1,809,363 |

— See Notes to Unaudited Condensed Interim Consolidated Financial Statements —

5

FLEXIBLE SOLUTIONS INTERNATIONAL, INC.

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

(U.S. Dollars — Unaudited)

|  | 2025 |  |  | 2024 |
|  | Six Months Ended June 30, |
|  | 2025 |  |  | 2024 |
Operating activities |  |  |  |  |  |  |  |
Net income for the period |  | $ | 1,881,193 |  |  | $ | 1,948,642 |
Adjustments to reconcile net income to cash provided by operations: |  |  |  |  |  |  |  |
Stock based compensation |  |  | 195,840 |  |  |  | 379,260 |
Depreciation and amortization |  |  | 960,093 |  |  |  | 939,524 |
Gain on investment |  |  | (85,660 | ) |  |  | (298,438 | )
Changes in operating assets and liabilities: |  |  |  |  |  |  |  |
Accounts receivable, net |  |  | 3,097,017 |  |  |  | 1,050,360 |
Inventories |  |  | (444,706 | ) |  |  | 800,931 |
Prepaid expenses and deposits |  |  | 798,654 |  |  |  | 959,890 |
Long term deposits |  |  | (1,292,464 | ) |  |  | (1,703,091 | )
Accounts payable |  |  | (331,512 | ) |  |  | (495,756 | )
Accrued liabilities |  |  | (194,872 | ) |  |  | 974,479 |
Income taxes payable |  |  | 195,509 |  |  |  | 822,429 |
Deferred revenue |  |  | (40,455 | ) |  |  | (68,375 | )
Cash provided by operating activities |  |  | 4,738,637 |  |  |  | 5,309,855 |
Investing activities |  |  |  |  |  |  |  |
Distributions received from equity investments |  |  | - |  |  |  | 427,000 |
Purchase of property and equipment |  |  | (1,331,042 | ) |  |  | (1,663,697 | )
Cash used in investing activities |  |  | (1,331,042 | ) |  |  | (1,236,697 | )
Financing activities |  |  |  |  |  |  |  |
Repayment of short term line of credit, net |  |  | (1,342,067 | ) |  |  | (1,190,635 | )
Repayment of long term debt |  |  | (1,234,489 | ) |  |  | (373,615 | )
Proceeds from long term debt |  |  | - |  |  |  | 524,812 |
Dividends paid |  |  | (1,274,753 | ) |  |  | (1,255,053 | )
Distributions to non-controlling interest |  |  | (252,169 | ) |  |  | (365,644 | )
Proceeds from shares issued upon exercise of stock options |  |  | 393,890 |  |  |  | 26,250 |
Cash used in financing activities |  |  | (3,709,588 | ) |  |  | (2,633,885 | )
Effect of exchange rate changes on cash |  |  | 269,354 |  |  |  | 62,341 |
Increase (decrease) in cash and term deposits |  |  | (32,639 | ) |  |  | 1,501,614 |
Cash and term deposits, beginning |  |  | 10,031,971 |  |  |  | 7,707,824 |
Cash and term deposits, ending |  | $ | 9,999,332 |  |  | $ | 9,209,438 |
Cash and term deposits consist of: |  |  |  |  |  |  |  |
Cash |  | $ | 8,613,182 |  |  | $ | 6,843,825 |
Term deposits |  |  | 1,386,150 |  |  |  | 2,365,613 |
Cash and cash equivalents, ending |  | $ | 9,999,332 |  |  | $ | 9,209,438 |

— See Notes to Unaudited Condensed Interim Consolidated Financial Statements —

6

FLEXIBLE SOLUTIONS INTERNATIONAL, INC.

CONDENSED INTERIM Consolidated Statements of Stockholders’ Equity

(U.S. Dollars – Unaudited)

|  | Shares |  |  | Capital Stock |  |  | Capital in Excess of Par Value |  |  | Accumulated Earnings |  |  | Accumulated Other Comprehensive Loss |  |  | Total |  |  | Non- Controlling Interests |  |  | Total Stockholders’ Equity |
Balance December 31, 2024 |  |  | 12,515,532 |  |  | $ | 12,516 |  |  | $ | 18,789,915 |  |  | $ | 19,836,527 |  |  | $ | (606,986 | ) |  | $ | 38,031,972 |  |  | $ | 3,334,054 |  |  | $ | 41,366,026 |
Translation adjustment |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 188,840 |  |  |  | 188,840 |  |  |  | — |  |  |  | 188,840 |
Net income (loss) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (277,734 | ) |  |  | — |  |  |  | (277,734 | ) |  |  | 13,693 |  |  |  | (264,041 | )
Common stock issued upon exercise of options |  |  | 132,000 |  |  |  | 132 |  |  |  | 381,558 |  |  |  | — |  |  |  | — |  |  |  | 381,690 |  |  |  | — |  |  |  | 381,690 |
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | 97,920 |  |  |  | — |  |  |  | — |  |  |  | 97,920 |  |  |  | — |  |  |  | 97,920 |
Balance March 31, 2025 |  |  | 12,647,532 |  |  | $ | 12,648 |  |  | $ | 19,269,393 |  |  | $ | 19,558,793 |  |  | $ | (418,146 | ) |  | $ | 38,422,688 |  |  | $ | 3,347,747 |  |  | $ | 41,770,435 |
Translation adjustment |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 80,514 |  |  |  | 80,514 |  |  |  | — |  |  |  | 80,514 |
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 2,028,912 |  |  |  | — |  |  |  | 2,028,912 |  |  |  | 116,322 |  |  |  | 2,145,234 |
Common stock issued upon exercise of options |  |  | 5,000 |  |  |  | 5 |  |  |  | 12,195 |  |  |  | — |  |  |  | — |  |  |  | 12,200 |  |  |  | — |  |  |  | 12,200 |
Dividends paid |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (1,274,753 | ) |  |  | — |  |  |  | (1,274,753 | ) |  |  | — |  |  |  | (1,274,753 | )
Distributions to noncontrolling interests |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (252,169 | ) |  |  | (252,169 | )
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | 97,920 |  |  |  | — |  |  |  | — |  |  |  | 97,920 |  |  |  | — |  |  |  | 97,920 |
Balance June 30, 2025 |  |  | 12,652,532 |  |  | $ | 12,653 |  |  | $ | 19,379,508 |  |  | $ | 20,312,952 |  |  | $ | (337,632 | ) |  | $ | 39,367,481 |  |  | $ | 3,211,900 |  |  | $ | 42,579,381 |

|  | Shares |  |  | Capital Stock |  |  | Capital in Excess of Par Value |  |  | Accumulated Earnings |  |  | Accumulated Other Comprehensive Loss |  |  | Total |  |  | Non- Controlling Interests |  |  | Total Stockholders’ Equity |
Balance December 31, 2023 |  |  | 12,435,532 |  |  | $ | 12,436 |  |  | $ | 17,932,015 |  |  | $ | 18,053,051 |  |  | $ | (795,146 | ) |  | $ | 35,202,356 |  |  | $ | 3,065,716 |  |  | $ | 38,268,072 |
Translation adjustment |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 27,223 |  |  |  | 27,223 |  |  |  | — |  |  |  | 27,223 |
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 457,226 |  |  |  | — |  |  |  | 457,226 |  |  |  | 58,983 |  |  |  | 516,209 |
Common stock issued |  |  | 15,000 |  |  |  | 15 |  |  |  | 26,235 |  |  |  | — |  |  |  | — |  |  |  | 26,250 |  |  |  | — |  |  |  | 26,250 |
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | 253,357 |  |  |  | — |  |  |  | — |  |  |  | 253,357 |  |  |  | — |  |  |  | 253,357 |
Balance March 31, 2024 |  |  | 12,450,532 |  |  | $ | 12,451 |  |  | $ | 18,211,607 |  |  | $ | 18,510,277 |  |  | $ | (767,923 | ) |  | $ | 35,966,412 |  |  | $ | 3,124,699 |  |  | $ | 39,091,111 |
Balance |  |  | 12,450,532 |  |  | $ | 12,451 |  |  | $ | 18,211,607 |  |  | $ | 18,510,277 |  |  | $ | (767,923 | ) |  | $ | 35,966,412 |  |  | $ | 3,124,699 |  |  | $ | 39,091,111 |
Translation adjustment |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 35,118 |  |  |  | 35,118 |  |  |  | — |  |  |  | 35,118 |
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1,289,796 |  |  |  | — |  |  |  | 1,289,796 |  |  |  | 142,637 |  |  |  | 1,432,433 |
Dividends paid |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (1,255,053 | ) |  |  | — |  |  |  | (1,255,053 | ) |  |  | — |  |  |  | (1,255,053 | )
Distributions to noncontrolling interests |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (365,644 | ) |  |  | (365,644 | )
Stock-based compensation |  |  | — |  |  |  | — |  |  |  | 125,903 |  |  |  | — |  |  |  | — |  |  |  | 125,903 |  |  |  | — |  |  |  | 125,903 |
Net income (loss) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1,289,796 |  |  |  | — |  |  |  | 1,289,796 |  |  |  | 142,637 |  |  |  | 1,432,433 |
Balance June 30, 2024 |  |  | 12,450,532 |  |  | $ | 12,451 |  |  | $ | 18,337,510 |  |  | $ | 18,545,020 |  |  | $ | (732,805 | ) |  | $ | 36,162,176 |  |  | $ | 2,901,692 |  |  | $ | 39,063,868 |
Balance |  |  | 12,450,532 |  |  | $ | 12,451 |  |  | $ | 18,337,510 |  |  | $ | 18,545,020 |  |  | $ | (732,805 | ) |  | $ | 36,162,176 |  |  | $ | 2,901,692 |  |  | $ | 39,063,868 |

— See Notes to Unaudited Condensed Interim Consolidated Financial Statements —

7

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Six Months Ended June 30, 2025

(U.S. Dollars - Unaudited)

1. BASIS OF PRESENTATION

These condensed interim consolidated financial statements (“consolidated financial statements”) include the accounts of Flexible Solutions International, Inc. (the “Company”), its wholly-owned subsidiaries Flexible Fermentation Ltd., NanoChem Solutions Inc. (“NanoChem”), Flexible Solutions Ltd., Flexible Biomass LP, FS Biomass Inc., NCS Deferred Corp., Natural Chem SEZC Ltd., Pana Chem Solutions Inc., InnFlex Holdings Inc., ENP Peru Investments LLC (“ENP Peru”), its 80% controlling interest in 317 Mendota LLC (“317 Mendota”), and its 65% controlling interest in ENP Investments, LLC (“ENP Investments”) and ENP Mendota, LLC (“ENP Mendota”). All inter-company balances and transactions have been eliminated upon consolidation. The Company was incorporated on May 12, 1998 in the State of Nevada and in 2019, the Company redomiciled into Alberta, Canada.

In 2022, NanoChem purchased an additional 50% in ENP Peru, increasing its share to 91.67%. ENP Investments owned the remaining 8.33%, of which the Company has a 65% interest. In 2023, NanoChem purchased the remaining 8.33% of shares to become sole owner. ENP Peru was previously accounted for under the equity method however, it is now consolidated into the financial statements from the date control was obtained.

In 2023, the Company purchased an 80% interest in 317 Mendota, a newly incorporated company established to purchase a large manufacturing building. ENP Investments occupies part of this building, freeing up more space in the building owned by ENP Peru for NanoChem. The Company intends to rent the remainder of the space to suitable tenants. The remaining 20% non-controlling interest is held by unrelated parties.

The Company and its subsidiaries develop, manufacture and market specialty chemicals which slow the evaporation of water. One product, HEATSAVR®, is marketed for use in swimming pools and spas where its use, by slowing the evaporation of water, allows the water to retain a higher temperature for a longer period of time and thereby reduces the energy required to maintain the desired temperature of the water in the pool. Another product, WATERSAVR®, is marketed for water conservation in irrigation canals, aquaculture, and reservoirs where its use slows water loss due to evaporation. In addition to the water conservation products, the Company also manufactures and markets water-soluble chemicals utilizing thermal polyaspartate biopolymers (hereinafter referred to as “TPAs”), which are beta-proteins manufactured from the common biological amino acid, L-aspartic. TPAs can be formulated to prevent corrosion and scaling in water piping within the petroleum, chemical, utility and mining industries. TPAs are also used as proteins to enhance fertilizers in improving crop yields and can be used as additives for household laundry detergents, consumer care products and pesticides. The TPA division also manufactures two nitrogen conservation products for agriculture that slows nitrogen loss from fields and has installed custom equipment used to produce food and nutritional materials. All the ingredients the Company produces are custom products for specific clients and are confidential. The Company anticipates that this market vertical will grow over time. The Company also manufactures food grade products that are made and sold by the TPA division. The TPA division recognizes research and development income from time to time.

2. SIGNIFICANT ACCOUNTING POLICIES

These condensed interim consolidated financial statements have been prepared on a historical cost basis, except where otherwise noted, in accordance with accounting principles generally accepted in the United States applicable to a going concern and reflect the policies outlined below.

In the opinion of management, the accompanying unaudited condensed interim consolidated financial statements contain all adjustments (all of which are of a normal recurring nature) and disclosures necessary for a fair statement of the Company’s financial position as of June 30, 2025 and the results of its operations and cash flows for the six months then ended. The consolidated balance sheet as of December 31, 2024 is derived from the December 31, 2024 audited financial statements. The unaudited condensed interim consolidated financial statements do not include all disclosures required of annual consolidated financial statements and, accordingly, should be read in conjunction with our annual financial statements for the year ended December 31, 2024. Operating results for the three and six months ended June 30, 2025 may not be indicative of results expected for the full year ending December 31, 2025.

8

For the three and six months ended June 30, 2025, the Company’s estimated effective tax rate differs from the U.S. federal statutory rate primarily due to the accrual of interest and penalties related to uncertain tax positions. These amounts are recognized as a component of income tax expense. The Company continues to monitor and assess its uncertain tax positions and adjusts its estimates as new information becomes available.

(a) Term Deposits.

The Company has three term deposits that are maintained by commercials banks. The first term deposit is for $313,225 and matures in February 2026. This deposit pays 3% interest and if withdrawn before maturity, a penalty may be applied. The second term deposit is for $752,682, matures in September 2025 and pays interest at a rate of 1.65%. If withdrawn before maturity, the greater of the loss of accrued interest or $150, plus 1% of the principal shall be levied. The third term deposit is for $320,243, matures in August 2025 and pays interest at a rate of 3%. If withdrawn before maturity, a penalty may be applied.

(b) Inventories and Cost of Sales.

The Company has three major classes of inventory: completed goods, work in progress and raw materials and supplies. In all classes inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis or weighted average cost formula to inventories in different subsidiaries. Cost of sales includes all expenditures incurred in bringing the goods to the point of sale. Inventory costs and costs of sales include direct costs of the raw material, inbound freight charges, warehousing costs, handling costs (receiving and purchasing) and utilities and overhead expenses related to the Company’s manufacturing and processing facilities. Shipping and handling charges included in the accompanying condensed interim consolidated statements of operations are as follows:

SCHEDULE OF SHIPPING AND HANDLING CHARGES

|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | Three months ended June 30, |  |  | Six months ended June 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Shipping income in product sales |  | $ | 134,164 |  |  | $ | 160,537 |  |  | $ | 210,230 |  |  | $ | 288,826 |
Shipping costs in cost of sales |  | $ | 210,839 |  |  | $ | 292,664 |  |  | $ | 369,607 |  |  | $ | 509,167 |

(c) Research and Development Services.

Income from research and development services is recognized over a period of time as the Company satisfies contractual performance obligations. Costs related to these services are expensed as research and development costs are incurred.

(d) Risk Management.

The Company’s credit risk is primarily attributable to its accounts receivable. The amounts presented in the accompanying condensed interim consolidated balance sheets are net of allowances for doubtful accounts, estimated by the Company’s management based on prior experience and the current economic environment. The Company is exposed to credit-related losses in the event of non-payment by customers. Credit exposure is minimized by dealing with only credit worthy counterparties.

Excluding research and development services revenue that is listed separately, total revenue for the Company’s three primary customers in each period is as follows:

SCHEDULE OF TOTAL REVENUE

|  |  | Three months ended June 30, |  |  |  | Six months ended June 30, |
|  |  | 2025 |  |  |  | 2024 |  |  |  | 2025 |  |  |  | 2024 |
Total revenue for three primary customers |  | $ | 4,007,159 |  |  | $ | 5,520,361 |  |  | $ | 7,672,394 |  |  | $ | 9,843,563 |
Total revenue for three primary customers as a percentage of sales |  |  | 45 | % |  |  | 52 | % |  |  | 47 | % |  |  | 50 | %
Research and development services |  | $ | 2,500,000 |  |  | $ | - |  |  | $ | 2,500,000 |  |  | $ | - |
Research and development services as a percentage of sales |  |  | 22 | % |  |  | - |  |  |  | 13 | % |  |  | - |

Total accounts receivable for the Company’s three primary customers for the three and six months ended June 30, 2025 and research and development services accounts is as follows:

|  |  | June 30, 2025 |  |  |  | December 31, 2024 |
Accounts receivable of three primary customers |  | $ | 2,379,915 (28%) |  |  | $ | 7,585,199 (65%) |
Accounts receivable – research and development services |  | $ | 2,500,000 (29%) |  |  |  | - |

See Note 3 for allowance for doubtful accounts, all unrelated to our primary or research and development customers.

9

The credit risk on cash is limited because the Company limits its exposure to credit loss by placing its cash with major financial institutions. The Company maintains cash balances at financial institutions which at times exceed federally insured amounts. The Company has not experienced any losses in such accounts.

The Company is exposed to foreign exchange risk to the extent that market value rate fluctuations materially differ for financial assets and liabilities denominated in foreign currencies.

In order to manage its exposure to foreign exchange risks, the Company closely monitors the fluctuations in the foreign currency exchange rates and the impact on the value of cash, accounts receivable, and accounts payable and accrued liabilities. The Company has not hedged its exposure to currency fluctuations.

The Company is exposed to interest rate risk to the extent that the fair value or future cash flows for financial liabilities will fluctuate as a result of changes in market interest rates. The Company is exposed to interest rate risk on its long-term debt subject to fixed long-term interest rates.

In order to manage its exposure to interest rate risk, the Company closely monitors fluctuations in market interest risks and will refinance its long-term debt where possible to obtain more favourable rates.

(e) Reclassification.

Certain prior year amounts have been reclassified to conform to the 2025 financial statements presentation. Reclassifications had no effect on net income, cash flows, or stockholders’ equity as previously reported.

(f) Recent Accounting Pronouncements.

In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09 (Topic 740) Improvements to Income Tax Disclosures. The new guidance is intended to enhance annual income tax disclosures to address investor requests for more information about the tax risks and opportunities present in an entity’s operations. The amendments in this standard require disclosure of additional information in specified categories with respect to the reconciliation of the effective tax rate to the statutory rate (the rate reconciliation) for federal, state, and foreign income taxes. They also require greater detail about individual reconciling items in the rate reconciliation to the extent the impact of those items exceeds a specified threshold. In addition to new disclosures associated with the rate reconciliation, the amendments in this update require information pertaining to taxes paid (net of refunds received) to be disaggregated for federal, state, and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold. The amendments in this update are effective on January 1, 2025 for annual periods beginning after December 15, 2024, and early adoption is permitted. The Company adopted the standard on January 1, 2025 and anticipates disclosure regarding income taxes will be expanded in the annual financial statements for the year ended December 31, 2025.

In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. The new disclosure requirements are effective for the Company’s annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating the ASU to determine its impact on our consolidated financial statements and disclosures.

10

3. ACCOUNTS RECEIVABLE

SCHEDULE OF ACCOUNTS RECEIVABLE

|  | June 30, 2025 |  |  | December 31, 2024 |
Accounts receivable - products |  | $ | 6,388,106 |  |  | $ | 11,983,200 |
Accounts receivable – research and development services |  |  | 2,500,000 |  |  |  | - |
Allowances for doubtful accounts |  |  | (289,025 | ) |  |  | (287,102 | )
Total accounts receivable |  | $ | 8,599,081 |  |  | $ | 11,696,098 |

4. INVENTORIES

SCHEDULE OF INVENTORY

|  | June 30, 2025 |  |  | December 31, 2024 |
Completed goods |  | $ | 4,251,908 |  |  | $ | 3,060,508 |
Raw materials and supplies |  |  | 7,082,993 |  |  |  | 7,829,687 |
Total inventory |  | $ | 11,334,901 |  |  | $ | 10,890,195 |

5. PROPERTY AND EQUIPMENT

SCHEDULE OF PROPERTY AND EQUIPMENT

|  | June 30, 2025 |  |  | Accumulated |  |  | June 30, 2025 |
|  | Cost |  |  | Depreciation |  |  | Net |
Buildings and improvements |  | $ | 13,230,983 |  |  | $ | 4,836,025 |  |  | $ | 8,394,958 |
Automobiles |  |  | 199,845 |  |  |  | 135,109 |  |  |  | 64,736 |
Office equipment |  |  | 129,680 |  |  |  | 119,337 |  |  |  | 10,343 |
Manufacturing equipment |  |  | 16,165,002 |  |  |  | 7,478,498 |  |  |  | 8,686,504 |
Land |  |  | 440,592 |  |  |  | — |  |  |  | 440,592 |
Technology |  |  | 100,136 |  |  |  | 100,136 |  |  |  | — |
|  | $ | 30,266,238 |  |  | $ | 12,669,105 |  |  | $ | 17,597,133 |

|  | December 31, 2024 |  |  | Accumulated |  |  | December 31, 2024 |
|  | Cost |  |  | Depreciation |  |  | Net |
Buildings and improvements |  | $ | 12,795,750 |  |  | $ | 4,521,212 |  |  | $ | 8,274,538 |
Automobiles |  |  | 196,255 |  |  |  | 168,807 |  |  |  | 27,448 |
Office equipment |  |  | 124,526 |  |  |  | 117,011 |  |  |  | 7,515 |
Manufacturing equipment |  |  | 15,318,758 |  |  |  | 6,922,667 |  |  |  | 8,396,091 |
Land |  |  | 440,592 |  |  |  | — |  |  |  | 440,592 |
Technology |  |  | 94,945 |  |  |  | 94,945 |  |  |  | — |
|  | $ | 28,970,826 |  |  | $ | 11,824,642 |  |  | $ | 17,146,184 |

Amount of depreciation expense for the three months ended June 30, 2025 was $454,895 (2024 – $476,855); the amount of depreciation expense for the six months ended June 30, 2025 was $880,093 (2024 - $859,524) and is included in cost of sales in the unaudited interim condensed consolidated statements of income and comprehensive income.

6. INVESTMENTS

The Company’s investments at June 30, 2025 and December 31, 2024 consisted of the following:

SCHEDULE OF COMPANY’S INVESTMENTS

|  | June 30, 2025 |  |  | December 31, 2024 |
Investments, at cost: |  |  |  |  |  |  |  |
Lygos Inc., simple agreement for future equity (“SAFE”) agreement |  | $ | 1,000,000 |  |  | $ | 1,000,000 |
Trio Opportunity Corp., 97,000 non-voting Class B shares |  |  | 970,000 |  |  |  | 970,000 |
Investments, at cost: |  |  | 970,000 |  |  |  | 970,000 |
Investment, equity method: |  |  |  |  |  |  |  |
Florida-based LLC |  |  | 1,540,041 |  |  |  | 1,454,381 |
Total |  | $ | 3,510,041 |  |  | $ | 3,424,381 |

11

In January 2019, the Company invested in a Florida based LLC that is engaged in international sales of fertilizer additives. According to the operating agreement, the Company had a 50% interest in the profit and loss of the Florida based LLC but did not have control. In August 2024, the Company sold a 30.1% interest in the Florida based LLC to a third party for consideration of $2,000,000. In addition, the Company entered into a subsequent agreement for the sale of its remaining 19.9% interest over the next five years for an additional $4,000,000. Starting in 2025, the Company will sell a further 3.98% per year upon receipt of that year’s $800,000 payment. At June 30, 2025, the Company continues to account for this investment using the equity investment as it exercises significant influence.

A summary of the activity associated with the Company’s investment in the Florida based LLC during the six months ended June 30, 2025 and the year ended December 31, 2024 is follows:

SCHEDULE OF EQUITY METHOD INVESTMENT

Balance, December 31, 2023 – 50% interest |  |  | 4,063,960 |
Balance, December 31, 2023 – 50% interest |  |  | 4,063,960 |
Company’s proportionate share of earnings |  |  | 244,857 |
Distribution received |  |  | (510,710 | )
Basis of 30.1% of interest sold |  |  | (2,343,726 | )
Balance, December 31, 2024 – 19.9% interest |  | $ | 1,454,381 |
Company’s proportionate share of earnings |  |  | 85,660 |
Balance, June 30, 2025 – 19.9% interest |  | $ | 1,540,041 |

Summarized profit and loss information related to the Florida based LLC is as follows:

SUMMARY OF PROFIT AND LOSS INFORMATION RELATED TO EQUITY ACCOUNTED INVESTMENT

|  | Six months ended June 30, 2025 |  |  | Six months ended June 30, 2024 |
Net sales |  | $ | 7,042,739 |  |  | $ | 7,159,499 |
Gross profit |  | $ | 2,016,745 |  |  | $ | 2,044,578 |
Net income |  | $ | 430,453 |  |  | $ | 595,329 |

During the three months ended June 30, 2025, the Company had sales of $2,072,180 (2024 – $2,512,681) to the Florida based LLC and during the six months ended June 30, 2025, the Company had sales of $3,928,575 (2024 - $4,812,619) to the Florida based LLC, of which $1,978,433 is included within accounts receivable as at June 30, 2025 (December 31, 2024 - $1,866,645).

7. SHORT-TERM LINES OF CREDIT

(a) In June 2025, ENP Investments renewed the line of credit with Stock Yards Bank and Trust (“Stock Yards”). The revolving line of credit is for an aggregate amount of up to the lesser of (i) $5,000,000, or (ii) 50-80% of eligible domestic accounts receivable plus 50% of inventory, capped at $2,500,000. Interest on the unpaid principal balance of this loan will be calculated using the greater of prime or 4.0%. The interest rate at June 30, 2025 is 7.5% (December 31, 2024 - 7.5%).

The revolving line of credit contains customary affirmative and negative covenants, including the following: compliance with laws, provisions of financial statements and periodic reports, payment of taxes, maintenance of inventory and insurance, maintenance of operating accounts at Stock Yards, Stock Yard’s access to collateral, formation or acquisition of subsidiaries, incurrence of indebtedness, dispositions of assets, granting liens, changes in business, ownership or business locations, engaging in mergers and acquisitions, making investments or distributions and affiliate transactions. NanoChem is a guarantor of 65% of all the principal and other loan costs not to exceed $3,250,000. The non-controlling interest is the guarantor of the remaining 35% of all the principal and other loan costs not to exceed $1,750,000.

12

To secure the repayment of any amounts borrowed under the revolving line of credit, the Company granted Stock Yards a security interest in substantially all of the assets of ENP Investments, exclusive of intellectual property assets.

Short-term borrowings outstanding under the revolving line as of June 30, 2025 were $nil (December 31, 2024 - $2,052,159).

(b) In August 2024, the Company renewed the line of credit with Stock Yards Bank and Trust (“Stock Yards”). The revolving line of credit is for an aggregate amount of up to the lesser of (i) $2,000,000, or (ii) 80% of eligible domestic accounts receivable and certain foreign accounts receivable plus 50% of inventory, capped at $1,000,000. Interest on the unpaid principal balance of this loan will be calculated using the greater of prime or 4.0%. The interest rate at June 30, 2025 is 7.5% (December 31, 2024 - 8%).

The revolving line of credit contains customary affirmative and negative covenants, including the following: compliance with laws, provision of financial statements and periodic reports, payment of taxes, maintenance of inventory and insurance, maintenance of operating accounts at Stock Yards, Stock Yards access to collateral, formation or acquisition of subsidiaries, incurrence of indebtedness, dispositions of assets, granting liens, changes in business, ownership or business locations, engaging in mergers and acquisitions, making investments or distributions and affiliate transactions. The covenants also require that the Company maintain a minimum ratio of qualifying financial assets to the sum of qualifying financial obligations.

To secure repayment of any amounts borrowed under the revolving line of credit, the Company granted Stock Yards a security interest in substantially all of the assets of NanoChem, exclusive of intellectual property assets.

Short-term borrowings outstanding under the revolving line as of June 30, 2025 were $710,092 (December 31, 2024 were $nil).

8. LONG TERM DEBT

Long term debt, all of which is with Stock Yards Bank and Trust, at June 30, 2025 and December 31, 2024 consisted of the following:

SCHEDULE OF LONG TERM DEBT

|  | June 30, 2025 |  |  | December 31, 2024 |
ENP Mendota, 10-year mortgage, 5 year fixed index plus 4.50% interest (7.18%) monthly payments through to January 2030, collateralized by real property and all rents on said property |  | $ | 367,991 |  |  | $ | 387,577 |
NanoChem, 3-year note payable, 4.90% interest, monthly principal and interest payments through June 2025, collateralized by real property |  |  | - |  |  |  | 345,036 |
ENP Peru, 10-year mortgage, 7.18% interest (December 31, 2024 – 4.35%), monthly principal and interest payments through January 2030, collateralized by real property (1st mortgage) |  |  | 2,626,326 |  |  |  | 2,658,381 |
ENP Peru, 10-year mortgage, 5.4% interest, monthly principal payments plus interest through June 2032, collateralized by real property (2nd mortgage) |  |  | 240,664 |  |  |  | 243,957 |
NanoChem, 3-year note payable, 6.5% interest, interest only payments through to July 2024, then monthly principal and interest payments through December 2025, collateralized by manufacturing equipment |  |  | 688,785 |  |  |  | 1,355,285 |
317 Mendota, 5-year note payable, 6.79% interest, interest only payments through June 2024, then monthly principal and interest payments through June 2028 with lump sum payment of $2,024,710 due in June 2028, collateralized by real property |  |  | 2,197,566 |  |  |  | 2,223,667 |
NanoChem, 5-year note payable, 7.0% interest, monthly principal payments plus interest through August 2029, collateralized by manufacturing equipment |  |  | 1,404,027 |  |  |  | 1,545,945 |
Long-term debt |  |  | 7,525,359 |  |  |  | 8,759,848 |
Less: current portion |  |  | (1,144,165 | ) |  |  | (2,140,981 | )
Long-term debt non current |  | $ | 6,381,194 |  |  | $ | 6,618,867 |

13

The following table summarizes the scheduled annual future principal payments as of June 30, 2025:

SCHEDULE OF ANNUAL FUTURE PRINCIPAL PAYMENTS

Year Ended December 31, |  | Principal Amount Due |
Remainder of 2025 |  | $ | 914,143 |
2026 |  |  | 469,184 |
2027 |  |  | 500,192 |
2028 |  |  | 2,531,492 |
Thereafter |  |  | 3,110,348 |
Total |  | $ | 7,525,359 |

9. STOCK OPTIONS

The Company has a stock option plan (“Plan”). The purpose of this Plan is to provide additional incentives to key employees, officers, directors and consultants of the Company and its subsidiaries in order to help attract and retain the best available personnel for positions of responsibility and otherwise promote the success of the Company’s business. It is intended that options issued under this Plan constitute non-qualified stock options. The general terms of awards under the option plan are that 100% of the options granted will vest the year following the grant unless an executive employee is granted a multi-year stock option grant where an equal amount vests over the next 5 years. The maximum term of options granted is 5 years and the exercise price for all options are issued for not less than fair market value at the date of the grant.

The following table summarizes the Company’s stock option activities for the year ended December 31, 2024 and the six months ended June 30, 2025:

SCHEDULE OF STOCK OPTION ACTIVITIES

|  | Number of shares |  |  | Exercise price per share |  |  | Weighted average exercise price |
Balance, December 31, 2023 |  |  | 1,114,000 |  |  | $ | 1.75 – 3.61 |  |  | $ | 3.13 |
Granted |  |  | 1,081,000 |  |  | $ | 2.00 – 4.05 |  |  | $ | 2.12 |
Cancelled or expired |  |  | (275,000 | ) |  | $ | 1.75 – 3.61 |  |  | $ | 2.54 |
Exercised |  |  | (80,000 | ) |  | $ | 1.75 – 2.44 |  |  | $ | 2.31 |
Balance, December 31, 2024 |  |  | 1,840,000 |  |  | $ | 2.00 – 4.05 |  |  | $ | 2.68 |
Exercised |  |  | (137,000 | ) |  | $ | 2.00 – 3.61 |  |  | $ | 2.88 |
Balance, June 30, 2025 |  |  | 1,703,000 |  |  | $ | 2.00 – 4.05 |  |  | $ | 2.67 |
Exercisable, June 30, 2025 |  |  | 802,000 |  |  | $ | 2.00 – 3.61 |  |  | $ | 2.68 |

During the three months ended June 30, 2025 and 2024, the Company recognized stock based compensation associated with stock options as follows:

SCHEDULE OF RECOGNIZED STOCK BASED COMPENSATION

|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | Three months ended June 30, |  |  | Six months ended June 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Line item on the statement of operations and comprehensive income (loss): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Wages, administrative salaries and benefits |  | $ | 79,740 |  |  | $ | 119,868 |  |  | $ | 159,480 |  |  | $ | 363,285 |
Consulting |  |  | 18,180 |  |  |  | 6,035 |  |  |  | 36,360 |  |  |  | 15,975 |
Stock based compensation |  | $ | 97,920 |  |  | $ | 125,903 |  |  | $ | 195,840 |  |  | $ | 379,260 |

14

During the six months ended June 30, 2025, the Company granted nil (2024 – 56,000) stock options to consultants and nil (2024 – 894,000) stock options to employees. The fair value of options granted during 2024 was calculated using the following range of assumptions:

SCHEDULE OF STOCK OPTION FAIR VALUE ASSUMPTIONS

|  | 2024 |
Expected life – years |  |  | 3.0 |
Interest rate |  |  | 1.76 – 4.11 | %
Volatility |  |  | 66.01 – 71.59 | %
Fair value of options granted |  |  | $1.46 – 2.02 |

As of June 30, 2025, the weighted-average remaining contractual life of outstanding and exercisable options is 3.1 years and 2.8 years, respectively. As of June 30, 2025, there was approximately $408,011 of compensation expense related to non-vested awards that is expected to be recognized over a weighted average period of 1.4 years.

The aggregate intrinsic value of options outstanding and exercisable at June 30, 2025 is $3,720,890 (2024 - $nil) and $1,737,590 (2024 - $nil), respectively. During the six months ended June 30, 2025, the intrinsic value of stock options exercised was $428,925 (2024 - $720).

10. CAPITAL STOCK

During the six months ended June 30, 2025, 137,000 shares were issued upon the exercise of stock options (2024 – 15,000).

In the six months ended June 30, 2025, the Company declared a $0.10 special dividend payable on May 28, 2025 to shareholders of record on May 19, 2025 to shareholders for a total payment of $1,274,753.

In the six months ended June 30, 2024, the Company announced a special dividend of $0.10 per share that was paid on May 16, 2024 to shareholders for a total payment of $1,255,053.

11. NON-CONTROLLING INTERESTS

(a) ENP Investments is a limited liability corporation (“LLC”) that manufactures and distributes golf, turf and ornamental agriculture products in Mendota, Illinois. The Company owns a 65% interest in ENP Investments through its wholly-owned subsidiary NanoChem. An unrelated party (“NCI”) owns the remaining 35% interest in ENP Investments. ENP Mendota is a wholly owned subsidiary of ENP Investments. ENP Mendota is a LLC that leases warehouse space. For financial reporting purposes, the assets, liabilities and earnings of both of the LLC’s are consolidated into these condensed interim consolidated financial statements. The NCI’s ownership interest in ENP Investments is recorded in non-controlling interests in these condensed interim consolidated financial statements. The non-controlling interest represents NCI’s interest in the earnings and equity of ENP Investments. ENP Investments is allocated to the TPA segment. See Note 12.

ENP Investments makes cash distributions to its equity owners based on formulas defined within its Ownership Interest Purchase Agreement dated October 1, 2018. Distributions are defined in the Ownership Interest Purchase Agreement as cash on hand to the extent it exceeds current and anticipated long-term and short-term needs, including, without limitation, needs for operating expenses, debt service, acquisitions, reserves, and mandatory distributions, if any.

From the effective date of acquisition onward, the minimum distributions requirements under the Ownership Interest Purchase Agreement were satisfied. The total distribution from the effective date of acquisition onward was $4,272,848.

15

SCHEDULE OF DISTRIBUTIONS

Balance, December 31, 2023 |  | $ | 2,901,199 |
Distribution |  |  | (794,722 | )
Non-controlling interest share of income |  |  | 1,164,037 |
Balance, December 31, 2024 |  |  | 3,270,514 |
Distribution |  |  | (252,169 | )
Non-controlling interest share of income |  |  | 184,784 |
Balance, June 30, 2025 |  | $ | 3,203,129 |

During the three months ended June 30, 2025, the Company had sales of $1,094,243 (2024 – $1,134,720) to the NCI and during the six months ended June 30, 2025, the Company had sales of $1,924,726 (2024 - $2,426,145) to the NCI, of which $139,563 is included within accounts receivable as at June 30, 2025 (December 31, 2024 - $5,377,088).

b) 317 Mendota is a LLC that owns real estate that the Company occupies part of while renting out the excess. The Company owns a 80% interest in 317 Mendota and an unrelated party (“317 NCI”) owns the remaining 20% interest in 317 Mendota. For financial reporting purposes, the assets, liabilities and earnings of 317 Mendota are consolidated into these condensed interim financial statements and the 317 NCI’s ownership interest in 317 Mendota is recorded in non-controlling interests in these condensed interim consolidated financial statements. The non-controlling interest represents 317 NCI’s interest in the earnings and equity of 317 Mendota. 317 Mendota is allocated to the TPA segment as that is the intended use of the building.

SCHEDULE OF NON CONTROLLING INTEREST RELATED TO ACQUISITION

Balance, December 31, 2023 |  | $ | 164,517 |
Non-controlling interest share of income (loss) |  |  | (100,977 | )
Balance, December 31, 2024 |  |  | 63,540 |
Non-controlling interest share of income (loss) |  |  | (54,769 | )
Balance, June 30, 2025 |  | $ | 8,771 |

12. SEGMENTS

The Company operates in two segments:

(a) Energy and water conservation products (as shown under the column heading “EWCP” below), which consists of a (i) liquid swimming pool blankets which save energy and water by inhibiting evaporation from the pool surface, and (ii) food-safe powdered form of the active ingredient within the liquid blankets and which are designed to be used in still or slow moving drinking water sources.

(b) Biodegradable polymers, also known as TPA’s (as shown under the column heading “BCPA” below), used by the petroleum, chemical, utility and mining industries to prevent corrosion and scaling in water piping. This product can also be used in detergents to increase biodegradability and in agriculture to increase crop yields by enhancing fertilizer uptake.

The third product line is nitrogen conservation products used for the agriculture industry. These products decrease the loss of nitrogen fertilizer after initial application and allow less fertilizer to be used. These products are made and sold by the Company’s BCPA division.

From time to time, the BCPA division also engages in performing research and development services for third parties.

The Company’s reportable segments are strategic business units that offer different, but synergistic products and services. They are managed separately because each business requires different technology and marketing strategies.

Segment information aligns with how the Company’s Chief Operating Decision Maker (“CODM”) reviews and manages our business. The Company’s CODM is the Company’s Chief Executive Officer. Profit or loss from operations before income taxes, not including nonrecurring gains and losses and foreign exchange gains and losses are reviewed by the CODM at a consolidated level. The CODM assesses performance for each of the Company’s segments and decides how to better allocate resources based on consolidated net income that is reported on the Consolidated Statements of Income. The Company’s objective in making resource allocation decisions is to optimize the consolidated financial results.

16

Three months ended June 30, 2025:

SCHEDULE OF REPORTABLE SEGMENTS

|  | EWCP |  |  | BPCA |  |  | Other (1) |  |  | Consolidated |
Product sales |  | $ | 132,738 |  |  | $ | 8,734,394 |  |  | $ | - |  |  | $ | 8,867,132 |
Research and development services sales |  |  | - |  |  |  | 2,500,000 |  |  |  | - |  |  |  | 2,500,000 |
Cost of sales |  |  | 20,228 |  |  |  | 5,961,638 |  |  |  | - |  |  |  | 5,981,866 |
Gross profit |  |  | 112,510 |  |  |  | 5,272,756 |  |  |  | - |  |  |  | 5,385,266 |
Wages, administrative salaries and benefits |  |  | 24,673 |  |  |  | 870,117 |  |  |  | - |  |  |  | 894,790 |
Office & miscellaneous |  |  | 9,331 |  |  |  | 223,311 |  |  |  | 194 |  |  |  | 232,836 |
Other segment items (2) |  |  | 53,943 |  |  |  | 714,350 |  |  |  | 192,233 |  |  |  | 960,526 |
Net operating income (loss) |  |  | 24,563 |  |  |  | 3,464,978 |  |  |  | (192,427 | ) |  |  | 3,297,114 |
Interest expense |  |  | - |  |  |  | 184,126 |  |  |  | - |  |  |  | 184,126 |
Depreciation and amortization (included in cost of sales) |  |  | 3,324 |  |  |  | 491,571 |  |  |  | - |  |  |  | 494,895 |
Capital expenditures |  |  | - |  |  |  | 976,921 |  |  |  | - |  |  |  | 976,921 |
Assets at June 30, 2025 (3) |  |  | 1,620,647 |  |  |  | 55,440,799 |  |  |  | 1,172,602 |  |  |  | 58,234,048 |

Three months ended June 30, 2024:

|  | EWCP |  |  | BPCA |  |  | Other (1) |  |  | Consolidated |
Product sales |  | $ | 167,496 |  |  | $ | 10,361,243 |  |  | $ | - |  |  | $ | 10,528,739 |
Cost of sales |  |  | 132,868 |  |  |  | 6,456,776 |  |  |  | - |  |  |  | 6,589,644 |
Gross profit |  |  | 34,628 |  |  |  | 3,904,467 |  |  |  | - |  |  |  | 3,939,095 |
Wages, administrative salaries and benefits |  |  | 22,435 |  |  |  | 861,726 |  |  |  | - |  |  |  | 884,161 |
Office & miscellaneous |  |  | 12,395 |  |  |  | 185,154 |  |  |  | 158 |  |  |  | 197,707 |
Other segment items (2) |  |  | 73,236 |  |  |  | 659,613 |  |  |  | 153,466 |  |  |  | 886,315 |
Net operating income (loss) |  |  | (73,438 | ) |  |  | 2,197,974 |  |  |  | (153,624 | ) |  |  | 1,970,912 |
Interest expense |  |  | - |  |  |  | 157,131 |  |  |  | - |  |  |  | 157,131 |
Depreciation and amortization (included in cost of sales) |  |  | 3,828 |  |  |  | 513,027 |  |  |  | - |  |  |  | 516,855 |
Capital expenditures |  |  | - |  |  |  | 1,185,574 |  |  |  | - |  |  |  | 1,185,574 |
Assets at December 31, 2024 (3) |  |  | 2,588,731 |  |  |  | 56,415,104 |  |  |  | 964,744 |  |  |  | 59,968,579 |

Six months ended June 30, 2025:

|  | EWCP |  |  | BPCA |  |  | Other (1) |  |  | Consolidated |
Product sales |  | $ | 172,923 |  |  | $ | 16,167,901 |  |  | $ | - |  |  | $ | 16,340,824 |
Research and development sales |  |  | - |  |  |  | 2,500,000 |  |  |  | - |  |  |  | 2,500,000 |
Cost of sales |  |  | 70,025 |  |  |  | 11,433,969 |  |  |  | - |  |  |  | 11,503,994 |
Gross profit |  |  | 102,898 |  |  |  | 7,233,932 |  |  |  | - |  |  |  | 7,336,830 |
Wages, administrative salaries and benefits |  |  | 42,266 |  |  |  | 1,747,761 |  |  |  | - |  |  |  | 1,790,027 |
Office & miscellaneous |  |  | 22,882 |  |  |  | 351,206 |  |  |  | 867 |  |  |  | 374,955 |
Other segment items (2) |  |  | 73,657 |  |  |  | 1,540,720 |  |  |  | 329,514 |  |  |  | 1,943,891 |
Net operating income (loss) |  |  | (35,907 | ) |  |  | 3,594,245 |  |  |  | (330,381 | ) |  |  | 3,227,957 |
Interest expense |  |  | - |  |  |  | 382,145 |  |  |  | - |  |  |  | 382,145 |
Depreciation and amortization (included in cost of sales) |  |  | 6,530 |  |  |  | 953,563 |  |  |  | - |  |  |  | 960,093 |
Capital expenditures |  |  | - |  |  |  | 1,331,042 |  |  |  | - |  |  |  | 1,331,042 |
Assets at June 30, 2025 (3) |  |  | 1,620,647 |  |  |  | 55,440,799 |  |  |  | 1,172,602 |  |  |  | 58,234,048 |

17

Six months ended June 30, 2024:

|  | EWCP |  |  | BPCA |  |  | Other (1) |  |  | Consolidated |
Product sales |  | $ | 209,104 |  |  | $ | 19,544,507 |  |  | $ | - |  |  | $ | 19,753,611 |
Cost of sales |  |  | 171,876 |  |  |  | 12,822,273 |  |  |  | - |  |  |  | 12,994,149 |
Gross profit |  |  | 37,228 |  |  |  | 6,722,234 |  |  |  | - |  |  |  | 6,759,462 |
Wages, administrative salaries and benefits |  |  | 50,840 |  |  |  | 1,902,338 |  |  |  | - |  |  |  | 1,953,178 |
Office & miscellaneous |  |  | 21,899 |  |  |  | 333,229 |  |  |  | 202 |  |  |  | 355,330 |
Other segment items (2) |  |  | 93,109 |  |  |  | 1,387,047 |  |  |  | 234,055 |  |  |  | 1,714,211 |
Net operating income (loss) |  |  | (128,620 | ) |  |  | 3,099,620 |  |  |  | (234,257 | ) |  |  | 2,736,743 |
Interest expense |  |  | - |  |  |  | 332,397 |  |  |  | - |  |  |  | 332,397 |
Depreciation and amortization (included in cost of sales) |  |  | 7,711 |  |  |  | 931,813 |  |  |  | - |  |  |  | 939,524 |
Capital expenditures |  |  | - |  |  |  | 1,663,697 |  |  |  | - |  |  |  | 1,663,697 |
Assets at December 31, 2024 (3) |  |  | 2,588,731 |  |  |  | 56,415,104 |  |  |  | 964,744 |  |  |  | 59,968,579 |
Assets |  |  | 2,588,731 |  |  |  | 56,415,104 |  |  |  | 964,744 |  |  |  | 59,968,579 |

| (1) | Other is not considered an operating segment and includes expenses and income not identifiable to an operating segment and is not included in operating segment results
| (2) | Other segment items for each reportable segment includes items such as insurance, consulting, research, professional fees, and travel.
| (3) | Segment assets include cash, term deposits, accounts receivable, inventory, prepaid expenses, property and equipment, security deposits, investments, intangible assets, and goodwill.

Sales by territory are shown below:

SCHEDULE OF REVENUE GENERATED IN UNITED STATES AND CANADA

|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | Three months ended June 30, |  |  | Six months ended June 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Canada |  | $ | 167,020 |  |  | $ | 134,605 |  |  | $ | 455,115 |  |  | $ | 223,083 |
United States and abroad |  | $ | 11,200,112 |  |  | $ | 10,394,134 |  |  | $ | 18,385,709 |  |  | $ | 19,530,528 |
Total |  | $ | 11,367,132 |  |  | $ | 10,528,739 |  |  | $ | 18,840,824 |  |  | $ | 19,753,611 |

The Company’s long-lived assets (property, equipment, intangibles, and goodwill) are located in Canada and the United States as follows:

SCHEDULE OF LONG-LIVED ASSETS ARE LOCATED IN CANADA AND UNITED STATE

|  | June 30, 2025 |  |  | December 31, 2024 |
Canada |  | $ | 116,122 |  |  | $ | 116,496 |
United States |  |  | 22,055,286 |  |  |  | 21,683,963 |
Total |  | $ | 22,171,408 |  |  | $ | 21,800,459 |

13. SUBSEQUENT EVENTS

In July 2025, the Company issued 4,000 shares upon the exercise of employee stock options.

18

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Overview

The Company manufactures and markets biodegradable polymers which are used in the oil, gas and agriculture industries. The Company also develops, manufactures and markets specialty chemicals that slow the evaporation of water.

Results of Operations

We have three product lines.

The first is a chemical used in swimming pools and spas. The product forms a thin, transparent layer on the water’s surface. The transparent layer slows the evaporation of water, allowing the water to retain a higher temperature for a longer period of time thereby reducing the energy required to maintain the desired temperature of the water. A modified version can also be used in reservoirs, potable water storage tanks, livestock watering pods, canals, and irrigation ditches for the purpose of reducing evaporation. These products are sold by our EWCP division.

The second product, biodegradable polymers (“TPAs”), is used by the petroleum, chemical, utility and mining industries to prevent corrosion and scaling in water piping. TPAs can also be used to increase biodegradability in detergents and in the agriculture industry to increase crop yields by enhancing fertilizer uptake. TPA’s are sold by our BCPA division.

The third product line is nitrogen conservation products used for the agriculture industry. These products decrease the loss of nitrogen fertilizer after initial application and allow less fertilizer to be used. These products are made and sold by the Company’s BCPA division.

From time to time, the BCPA division also engages in performing research and development services for third parties.

Material changes in the Company’s Statement of Operations for six and three months ended June 30, 2025 compared to the same period in the prior year are discussed below:

Three Months ended June 30, 2025

Item |  | Increase (I) or Decrease (D) |  | Reason
Sales |  |  |  |
EWCP products |  | D |  | Decreased customer orders.
BCPA products |  | D |  | Decreased customer orders.
Research and development services |  | I |  | Due to a successful project that completed in 2025.
Gross profit as a percentage of sales |  | I |  | Increase in research and development sales.
Consulting |  | D |  | Decreased reliance on consultants.
Professional fees |  | I |  | Increase in accounting fees related to tax filings and increase in audit fees related to growth of the Company.
Research |  | I |  | New product development.
Travel |  | D |  | Travel requirements were lower in for the first six months in 2025 than it was in 2024.
Gain on investment |  | D |  | Sale of 30.1% of profitable Florida based LLC in 2024 reduced the amount of our proportionate share of earnings.
Interest expense |  | I |  | Increased debt resulted in increased interest expense.
Interest income |  | D |  | Decrease in term deposits held.

19

Six Months ended June 30, 2025

Item |  | Increase (I) or Decrease (D) |  | Reason
Sales |  |  |  |
EWCP products |  | D |  | Decreased customer orders.
BCPA products |  | D |  | Decreased customer orders.
Research and development services |  | I |  | Due to a successful project that completed in 2025.
Gross profit as a percentage of sales |  | I |  | Increase in research and development sales.
Consulting |  | D |  | Decreased reliance on consultants.
Professional fees |  | I |  | Increase in accounting fees related to tax filings and increase in audit fees related to growth of the Company.
Research |  | I |  | New product development.
Travel |  | D |  | Travel requirements were lower in for the first six months in 2025 than it was in 2024.
Utilities |  | I |  | Addition of real estate not yet leased.
Gain on investment |  | D |  | Sale of 30.1% of profitable Florida based LLC in 2024 reduced the amount of our proportionate share of earnings.
Lease termination fee |  | D |  | One time cost incurred in March 2024 upon terminating lease in Naperville, IL.
Interest expense |  | I |  | Increased debt resulted in increased interest expense.
Interest income |  | D |  | Decrease in term deposit held.

20

Three customers accounted for 45% of our product sales during the three months ended June 30, 2025 (2024 –52%) and 47% of our product sales during the six months ended June 30, 2025 (2024 – 50%). The amount of revenue (all from the sale of TPA products) attributable to each customer is shown below.

|  | Three months ended June 30, |  |  | Six months ended June 30, |
Customer |  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Company A |  | $ | 1,094,243 |  |  | $ | 1,134,720 |  |  | $ | 1,924,726 |  |  | $ | 2,426,145 | *
Company B |  | $ | 2,072,180 |  |  | $ | 2,512,681 |  |  | $ | 3,928,575 |  |  | $ | 4,812,619 |
Company C |  | $ | 840,736 |  |  | $ | 941,326 | * |  | $ | 1,819,093 |  |  | $ | 2,456,867 |
Company D |  | $ | 592,000 | * |  | $ | 1,872,960 |  |  | $ | 592,000 | * |  | $ | 2,574,076 |
Company E |  | $ | 2,500,000 | ** |  | $ | - | ** |  | $ | 2,500,000 | ** |  | $ | - | **

*not a primary product sales customer in that period

**Research and development services sales are not included in product sales

Customers with balances greater than 10% of our receivables as of June 30, 2025 and 2024 are shown below:

|  | June 30, |
|  | 2025 |  |  | 2024 |
Company B |  | $ | 1,978,433 |  |  | $ | 1,390,812 |
Company E |  | $ | 2,500,000 |  |  | $ | - |
Company F |  | $ | 522,982 | * |  | $ | 974,992 |
*less than 10% |  |  |  |  |  |  |  |

Other factors that will most significantly affect future operating results will be:

| ● | the sale price of crude oil which is used in the manufacture of aspartic acid we import from China. Aspartic acid is a key ingredient in our TPA products;
| ● | activity in the oil and gas industry, as we sell our TPA products to oil and gas companies;
| ● | drought conditions, since we also sell our TPA products to farmers; and
| ● | new tariffs relating to raw materials imported from China.

Other than the foregoing we do not know of any trends, events or uncertainties that have had, or are reasonably expected to have, a material impact on our revenues or expenses.

Capital Resources and Liquidity

The Company’s sources and (uses) of cash for the six months ended June 30, 2025 and 2024 are shown below:

|  | 2025 |  |  | 2024 |
Cash provided by operating activities |  |  | 4,738,637 |  |  |  | 5,309,855 |
Distributions received from equity investments |  |  | - |  |  |  | 427,000 |
Purchase of property and equipment |  |  | (1,331,042 | ) |  |  | (1,663,697 | )
Repayment of short term line of credit, net |  |  | (1,342,067 | ) |  |  | (1,190,635 | )
Repayment of long term debt |  |  | (1,234,489 | ) |  |  | (373,615 | )
Proceeds from long term debt |  |  | - |  |  |  | 524,812 |
Dividends paid |  |  | (1,274,753 | ) |  |  | (1,255,053 | )
Distributions to non-controlling interest |  |  | (252,169 | ) |  |  | (365,644 | )
Proceeds from shares issued upon exercise of stock options |  |  | 393,890 |  |  |  | 26,250 |
Effects of exchange rate changes on cash |  |  | 269,354 |  |  |  | 62,341 |

The Company has sufficient cash resources to meets its future commitments and cash flow requirements for the coming year. As of June 30, 2025, working capital was $21,940,799 (December 31, 2024 - $22,714,190) and the Company has no substantial commitments that require significant outlays of cash over the coming fiscal year.

Other than as disclosed above, the Company does not anticipate any significant capital requirements for the twelve months ending June 30, 2026.

Other than as disclosed above, the Company does not know of any trends, demands, commitments, events or uncertainties that will result in, or that are reasonable likely to result in, its liquidity increasing or decreasing in any material way.

There have been no significant changes to the critical accounting estimates disclosed in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our 2024 Form 10-K.

21

Item 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

Under the direction and with the participation of our management, including our Principal Executive and Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2025. We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic reports with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and regulations, and that such information is accumulated and communicated to our management, including our principal executive and financial officer, as appropriate, to allow timely decisions regarding required disclosure. Our disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching desired disclosure control objectives. Based on the evaluation, our Principal Executive and Financial Officer concluded that these disclosure controls and procedures are effective as of June 30, 2025

Changes in Internal Control over Financial Reporting

Our management, with the participation of our Principal Executive and Financial Officer, evaluated whether any change in our internal control over financial reporting occurred during the three months ended June 30, 2025. Based on that evaluation, it was concluded that there has been no change in our internal control over financial reporting during the three months ended June 30, 2025 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II

Item 5. Other Information

None of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period ending June 30, 2025.

Item 6. Exhibits.

Number |  | Description
3.1 |  | Articles of Continuance (Articles of Incorporation) (1)
3.2 |  | Bylaws (2)
31.1 |  | Certification of Principal Executive Officer Pursuant to §302 of the Sarbanes-Oxley Act of 2002.*
31.2 |  | Certification of Principal Financial Officer Pursuant to §302 of the Sarbanes-Oxley Act of 2002.*
32.1 |  | Certification of Principal Executive and Financial Officer Pursuant to 18 U.S.C. §1350 and §906 of the Sarbanes-Oxley Act of 2002.*
101.INS |  | Inline XBRL Instance Document
101.SCH |  | Inline XBRL Taxonomy Extension Schema Document
101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 |  | Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed with this report.

(1) | Incorporated by reference the same exhibit filed with the Company’s March 31, 2022 10-Q report.
(2) | Incorporated by reference to Exhibit 3(ii) filed the Company’s 8-K report dated April 10, 2022.

22

SIGNATURES

In accordance with the requirements of Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

August 14, 2025

| Flexible Solutions International, Inc.
| By: | /s/ Daniel B. O’Brien
| Name: | Daniel B. O’Brien
| Title: | President and Principal Executive Officer
| By: | /s/ Daniel B. O’Brien
| Name: | Daniel B. O’Brien
| Title: | Principal Financial and Accounting Officer

23